On Thursday, Shares of TASER International Inc. (NASDAQ:TASR), surged 2.50% to $27.83.
TASER International, declared the purchase of 300 AXON Flex body cameras and a five-year subscription on the EVIDENCE.com Officer Safety Plan by the Mobile Police Department. This order was received in and is predictable to ship in the second quarter of 2015. TASER further declared its new Standard Issue Grant Program that offers up to $400 per officer for police agencies who are making TASER Smart Weapons and/or AXON body cameras standard issue for all officers within their department.
TASER has budgeted $40 million to get 100,000 patrol officers and all new officers graduating law enforcement academy signed up for its Standard Issue Grant Program by the end of 2015. The grants are accessible to both US and International agencies and the amounts vary depending on the accompanying warranty or plan. The grants represent upfront credits toward new equipment and / or service contracts applied at inception of the contract. The three grant levels comprise:
Level 1: $100 per officer for Smart Weapon or AXON camera with extended warranty
Level 2: $200 per officer for Smart Weapon or AXON camera with TASER Assurance Plan enrollment (comprises Smart Weapon upgrade every 5 years, AXON camera upgrade every 2.5 years)
Level 3: $400 per officer for Officer Safety Plan enrollment.
The Officer Safety Plan comprises all of the advanced features of EVIDENCE.com, unlimited storage for bodycam video, a service plan that comprises automatic upgrades of the AXON Cameras every 2.5 years and upgrades of the associated TASER devices every five years, in addition to full hardware equipment warranties and service.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The company’s CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system.
Shares of Incyte Corporation (NASDAQ:INCY), gained 2.46% to $102.76, during the last trading session on Thursday, hitting its highest level.
Incyte Corporation, declared that it has planned its first quarter 2015 financial results conference call for 8:00 a.m. ET on Thursday, April 30, 2015. The conference call will also be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology.
At the end of Thursday’s trade, Shares of Anthem, Inc. (NYSE:ANTM), gained 2.40% to $154.93.
Anthem, and CareEvolution declared their partnership to make the cFHR™ (collaborative Family Health Record) app accessible for Apple Watch. The cFHR™ app, accessible now as a free download from the App Store on iPhone, will be one of the first apps accessible for Apple Watch at the launch of the device on April 24, 2015.
The cFHR™ Apple Watch app will seamlessly connect consumers to their health care providers and Anthem’s family of health plans and provide consumers with actionable health and wellness notifications. The app is designed to make it convenient and simple for consumers to receive alerts, review new medical information and manage their health care from their wrist. Consumers would be notified of suggested preventive screenings, gaps in disease administration and prescription refills, and potential drug interactions – consider it a tap on the wrist reminder.
With more than 37 million customers in Anthem’s family of companies, Anthem has the scale and footprint to significantly influence how Americans track and manage their health and well-being. The cFHR™ Apple Watch app provides a more complete health picture for consumers and will enable them to live healthier lives.
The cFHR™ Watch App works seamlessly with the existing Apple HealthKit enabled iPhone cFHR™ app to give providers and consumers access to their medical history in one unified record. By leveraging Apple HealthKit, the cFHR™ platform enables care managers access to consumer health, fitness and diet information.
CareEvolution will be previewing the new application this week at the Interoperability Showcase at the HIMSS 2015 conference in Chicago, Illinois.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other.
Finally, Rosetta Genomics, Ltd. (NASDAQ:ROSG), ended its Thursday’s trading session with 2.16% gain, and closed at $3.78.
On April 15, Rosetta Genomics, declared receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”
The allowed patent claims a method for identifying a tissue of origin of a cancer sample by the expression levels of 64 microRNAs using a combination of probes attached to a solid substrate, and employing a classifier algorithm in order to identify the tissue of origin. This patent specifically covers the second generation of Rosetta’s Cancer Origin Test™, which uses more markers and identifies a larger spectrum of cancers than the previous generation. Further, it is based on microarray technology for microRNA expression profiling.
Rosetta Genomics has 42 issued patents, five allowed patents and 45 patents pending worldwide.
Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
